1
|
Mitkin NA, Unguryanu TN, Malyutina S, Kudryavtsev AV. Association between Alcohol Consumption and Body Composition in Russian Adults and Patients Treated for Alcohol-Related Disorders: The Know Your Heart Cross-Sectional Study. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2023; 20:2905. [PMID: 36833602 PMCID: PMC9957482 DOI: 10.3390/ijerph20042905] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Revised: 01/31/2023] [Accepted: 02/03/2023] [Indexed: 06/18/2023]
Abstract
There is conflicting evidence about the association between alcohol consumption and body composition (BC). We aimed to investigate this association in Russian adults. The study population included 2357 residents of Arkhangelsk aged 35-69 years, and 272 in-patients treated for alcohol problems (narcological patients) who participated in the Know Your Heart (KYH) cross-sectional study in 2015-2017. The participants were divided into five subgroups based on their alcohol use characteristics: non-drinkers, non-problem drinkers, hazardous drinkers, harmful drinkers, and narcological patients. Considering men, hazardous drinkers had a larger waist circumference (WC), waist-to-hip ratio (WHR), and percentage of body fat mass (%FM) compared to non-problem drinkers. In harmful drinking men, these differences were the opposite: a lower body mass index (BMI), hip circumference (HC), and %FM. Men among narcological patients had the lowest mean BMI, WC, HC, WHR, and %FM compared to other subgroups of men. As for women, non-drinkers had a lower BMI, WC, HC, and %FM compared to non-problem drinkers. Women among narcological patients had the lowest mean BMI and HC but an increased WHR compared to other subgroups of women. In conclusion, alcohol consumption levels had an inverted J-shaped association with adiposity-related BC parameters: they were elevated in hazardous drinkers but were reduced in harmful drinkers, and were even lower in patients with alcohol-related diagnoses.
Collapse
Affiliation(s)
- Nikita A. Mitkin
- Department of Community Medicine, UiT The Arctic University of Norway, N-9037 Tromsø, Norway
- International Research Competence Centre, Northern State Medical University, Troitsky Ave., 51, 163069 Arkhangelsk, Russia
| | - Tatiana N. Unguryanu
- Department of Hygiene and Medical Ecology, Northern State Medical University, Troitsky Ave., 51, 163069 Arkhangelsk, Russia
| | - Sofia Malyutina
- Research Institute of Internal and Preventive Medicine, Branch of Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Bogatkova st., 175/1, 630008 Novosibirsk, Russia
- Department of Therapy, Hematology and Transfusiology, Novosibirsk State Medical University, Krasny Ave., 52, 630091 Novosibirsk, Russia
| | - Alexander V. Kudryavtsev
- Department of Community Medicine, UiT The Arctic University of Norway, N-9037 Tromsø, Norway
- International Research Competence Centre, Northern State Medical University, Troitsky Ave., 51, 163069 Arkhangelsk, Russia
| |
Collapse
|
2
|
Requena-Ocaña N, Araos P, Serrano-Castro PJ, Flores-López M, García-Marchena N, Oliver-Martos B, Ruiz JJ, Gavito A, Pavón FJ, Serrano A, Mayoral F, Suarez J, de Fonseca FR. Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder. Int J Mol Sci 2023; 24:ijms24021183. [PMID: 36674698 PMCID: PMC9866623 DOI: 10.3390/ijms24021183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Revised: 12/12/2022] [Accepted: 01/03/2023] [Indexed: 01/11/2023] Open
Abstract
For a long time, Substance Use Disorders (SUDs) were not considered a component in the etiology of dementia. The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders introduced substance-induced neurocognitive disorders, incorporating this notion to clinical practice. However, detection and monitoring of neurodegenerative processes in SUD patients remain a major clinical challenge, especially when early diagnosis is required. In the present study, we aimed to investigate new potential biomarkers of neurodegeneration that could predict cognitive impairment in SUD patients: the circulating concentrations of Neurofilament Light chain protein (NfL) and Brain-Derived Neurotrophic Factor (BDNF). Sixty SUD patients were compared with twenty-seven dementia patients and forty healthy controls. SUD patients were recruited and assessed using the Psychiatric Research Interview for Substance and Mental (PRISM) and a battery of neuropsychological tests, including the Montreal Cognitive Assessment test for evaluation of cognitive impairment. When compared to healthy control subjects, SUD patients showed increases in plasma NfL concentrations and NfL/BDNF ratio, as well as reduced plasma BDNF levels. These changes were remarkable in SUD patients with moderate-severe cognitive impairment, being comparable to those observed in dementia patients. NfL concentrations correlated with executive function and memory cognition in SUD patients. The parameters "age", "NfL/BDNF ratio", "first time alcohol use", "age of onset of alcohol use disorder", and "length of alcohol use disorder diagnosis" were able to stratify our SUD sample into patients with cognitive impairment from those without cognitive dysfunction with great specificity and sensibility. In conclusion, we propose the combined use of NfL and BDNF (NfL/BDNF ratio) to monitor substance-induced neurocognitive disorder.
Collapse
Affiliation(s)
- Nerea Requena-Ocaña
- Neuropsychopharmacology Group, Instituto IBIMA, Hospital Regional Universitario de Málaga, Avda. Carlos Haya 82, Sótano, 29010 Malaga, Spain
- School of Psychology, Complutense University of Madrid, Campus de Somosaguas, 28040 Madrid, Spain
| | - Pedro Araos
- Neuropsychopharmacology Group, Instituto IBIMA, Hospital Regional Universitario de Málaga, Avda. Carlos Haya 82, Sótano, 29010 Malaga, Spain
| | - Pedro J. Serrano-Castro
- Andalusian Network for Clinical and Translational Research in Neurology (NEURO-RECA), 29010 Malaga, Spain
- Neurology Service, Regional University Hospital of Malaga, 29010 Malaga, Spain
| | - María Flores-López
- Neuropsychopharmacology Group, Instituto IBIMA, Hospital Regional Universitario de Málaga, Avda. Carlos Haya 82, Sótano, 29010 Malaga, Spain
| | - Nuria García-Marchena
- Neuropsychopharmacology Group, Instituto IBIMA, Hospital Regional Universitario de Málaga, Avda. Carlos Haya 82, Sótano, 29010 Malaga, Spain
- Institute D, Research in Health Sciences Germans Trias i Pujol (IGTP), Addictions Unit-Internal Medicine Service, Campus Can Ruti, Carrer del Canyet s/n, 08916 Badalona, Spain
| | - Begoña Oliver-Martos
- Andalusian Network for Clinical and Translational Research in Neurology (NEURO-RECA), 29010 Malaga, Spain
- Neurology Service, Regional University Hospital of Malaga, 29010 Malaga, Spain
| | - Juan Jesús Ruiz
- Provincial Drug Addiction Center (CPD) of Malaga, Provincial Council of Malaga, C/Ana Solo de Zaldívar, n3, 29010 Malaga, Spain
| | - Ana Gavito
- Neuropsychopharmacology Group, Instituto IBIMA, Hospital Regional Universitario de Málaga, Avda. Carlos Haya 82, Sótano, 29010 Malaga, Spain
| | - Francisco Javier Pavón
- Neuropsychopharmacology Group, Instituto IBIMA, Hospital Regional Universitario de Málaga, Avda. Carlos Haya 82, Sótano, 29010 Malaga, Spain
- Center for Biomedical Research in the Cardiovascular Diseases Network (CIBERCV), Carlos III Health Institute, Calle de Melchor Fernández Almagro, 3, 28029 Madrid, Spain
| | - Antonia Serrano
- Neuropsychopharmacology Group, Instituto IBIMA, Hospital Regional Universitario de Málaga, Avda. Carlos Haya 82, Sótano, 29010 Malaga, Spain
| | - Fermín Mayoral
- Mental Health Clinical Management Unit, Institute of Biomedical Research of Malaga-IBIMA, Regional University Hospital of Málaga, 29010 Malaga, Spain
| | - Juan Suarez
- Neuropsychopharmacology Group, Instituto IBIMA, Hospital Regional Universitario de Málaga, Avda. Carlos Haya 82, Sótano, 29010 Malaga, Spain
- Department of Anatomy, Legal Medicine and History of Science, School of Medicine, University of Malaga, Boulevard Louis Pasteur 32, 29071 Malaga, Spain
- Correspondence: (J.S.); (F.R.d.F.)
| | - Fernando Rodríguez de Fonseca
- Neuropsychopharmacology Group, Instituto IBIMA, Hospital Regional Universitario de Málaga, Avda. Carlos Haya 82, Sótano, 29010 Malaga, Spain
- Andalusian Network for Clinical and Translational Research in Neurology (NEURO-RECA), 29010 Malaga, Spain
- Neurology Service, Regional University Hospital of Malaga, 29010 Malaga, Spain
- Mental Health Clinical Management Unit, Institute of Biomedical Research of Malaga-IBIMA, Regional University Hospital of Málaga, 29010 Malaga, Spain
- Correspondence: (J.S.); (F.R.d.F.)
| |
Collapse
|
3
|
Clergue-Duval V, Vrillon A, Jeanblanc J, Questel F, Azuar J, Fouquet G, Mouton-Liger F, Rollet D, Hispard E, Bouaziz-Amar E, Bloch V, Dereux A, Cognat E, Marie-Claire C, Laplanche JL, Bellivier F, Paquet C, Naassila M, Vorspan F. Plasma tau, NfL, GFAP and UCHL1 as candidate biomarkers of alcohol withdrawal-associated brain damage: A pilot study. Addict Biol 2022; 27:e13232. [PMID: 36301211 DOI: 10.1111/adb.13232] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Revised: 08/24/2022] [Accepted: 08/26/2022] [Indexed: 01/24/2023]
Abstract
In this translational study, we investigated the plasma tau protein, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCHL1), which are established biomarkers of neurological injury, as predictive biomarkers of alcohol withdrawal-associated brain toxicity. In the clinical study, patients with severe alcohol use disorder (AUD) on D1 of hospitalization for alcohol cessation (AC) (N = 36) were compared to severe AUD patients with at least 3 months of abstinence (N = 16). Overall, patients were 40 men (76.9%), aged 49.8 years [SD ±9.9]. Tau, NfL, GFAP and UCHL1 levels were measured using SIMOA and analysed with a quasipoisson regression model adjusted for age and sex. The NfL level was higher in the AC group (p = 0.013). In the AC group, the tau (p = 0.021) and UCHL1 (p = 0.021) levels were positively associated with the dose of diazepam per weight, and the tau (p = 0.045), NfL (p = 4.9 × 10-3 ) and UCHL1 (p = 0.036) levels were higher in the presence of signs of Wernicke's encephalopathy (n = 9). In the preclinical study, NfL and GFAP levels were assessed in the alcohol deprivation effect (ADE) procedure (N = 17) and control Wistar rats (N = 15). Furthermore, ADE rats were prospectively assessed: after 24 h (T1) and 3 weeks of AC (T2) (paired-samples Wilcoxon and Mann-Whitney tests). The NfL level was higher in the ADE model than in the control rats at both T1 and T2 (p = 0.033 and p = 1.3 × 10-3 ) and higher at T2 than at T1 (p = 0.040). Plasma tau, NfL and UCHL1 are potential biomarkers of brain suffering during alcohol withdrawal.
Collapse
Affiliation(s)
- Virgile Clergue-Duval
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Médecine, Université Paris Cité, Paris, France.,Resalcog (Réseau pour la prise en charge des troubles cognitifs liés à l'alcool), Paris, France
| | - Agathe Vrillon
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Médecine, Université Paris Cité, Paris, France.,Centre de Neurologie Cognitive, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France
| | - Jérôme Jeanblanc
- Inserm UMRS-1247 Groupe de recherche sur l'alcool et les pharmacodépendances, Université de Picardie Jules Verne, Amiens, France.,FHU Améliorer le pronostic des troubles Addictifs et Mentaux par une Médecine Personnalisée (A2M2P), Amiens, France
| | - Frank Questel
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,Resalcog (Réseau pour la prise en charge des troubles cognitifs liés à l'alcool), Paris, France
| | - Julien Azuar
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,Resalcog (Réseau pour la prise en charge des troubles cognitifs liés à l'alcool), Paris, France
| | - Grégory Fouquet
- Inserm UMRS-1247 Groupe de recherche sur l'alcool et les pharmacodépendances, Université de Picardie Jules Verne, Amiens, France.,FHU Améliorer le pronostic des troubles Addictifs et Mentaux par une Médecine Personnalisée (A2M2P), Amiens, France
| | - François Mouton-Liger
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Médecine, Université Paris Cité, Paris, France.,Centre de Neurologie Cognitive, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France
| | - Dorian Rollet
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,Resalcog (Réseau pour la prise en charge des troubles cognitifs liés à l'alcool), Paris, France
| | - Eric Hispard
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,Resalcog (Réseau pour la prise en charge des troubles cognitifs liés à l'alcool), Paris, France
| | - Elodie Bouaziz-Amar
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,Département de Biochimie et Biologie Moléculaire, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,UFR de Pharmacie, Université Paris Cité, Paris, France
| | - Vanessa Bloch
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Pharmacie, Université Paris Cité, Paris, France.,Service de Pharmacie, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France
| | - Alexandra Dereux
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,Resalcog (Réseau pour la prise en charge des troubles cognitifs liés à l'alcool), Paris, France
| | - Emmanuel Cognat
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Médecine, Université Paris Cité, Paris, France.,Centre de Neurologie Cognitive, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France
| | - Cynthia Marie-Claire
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France
| | - Jean-Louis Laplanche
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,Département de Biochimie et Biologie Moléculaire, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,UFR de Pharmacie, Université Paris Cité, Paris, France
| | - Frank Bellivier
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Médecine, Université Paris Cité, Paris, France
| | - Claire Paquet
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Médecine, Université Paris Cité, Paris, France.,Centre de Neurologie Cognitive, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France
| | - Mickael Naassila
- Inserm UMRS-1247 Groupe de recherche sur l'alcool et les pharmacodépendances, Université de Picardie Jules Verne, Amiens, France.,FHU Améliorer le pronostic des troubles Addictifs et Mentaux par une Médecine Personnalisée (A2M2P), Amiens, France.,UFR de Pharmacie, Université de Picardie Jules Verne, Amiens, France
| | - Florence Vorspan
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Médecine, Université Paris Cité, Paris, France
| |
Collapse
|